- First Quarter 2022 Financial Results
- Revenue of $1,225 million
- Reported Net Income of $48 million, Adjusted Net Income of $177 million
- Adjusted EBITDA of $339 million or 27.7% of Revenue
- Reported EPS of $0.10, Adjusted EPS of $0.36
- Updating full year 2022 revenue guidance to be $4,700 to $4,755 million, due to the negative impact of foreign exchange rates; constant currency revenue growth guidance remains unchanged.
- Increasing guidance for full year 2022 diluted EPS to $0.02 to $0.09 on a reported basis and updating guidance to $1.15 to $1.21 on an adjusted basis, due to the negative impact of foreign exchange rates.
- Providing financial guidance for the second quarter 2022 with revenue of $1,160 to $1,200 million, and diluted EPS of $(0.05) to $0.02 on a reported basis, or $0.22 to $0.28 on an adjusted basis.
- Announced strategic alliance with Royal DSM, for exclusive U.S. rights to Bovaer®, a methane-reducing feed product for cattle.
GREENFIELD, IN (May 9, 2022) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2022, provided guidance for the second quarter of 2022, and updated guidance for the full year 2022.
